THRIVE: Trial for Harm Reduction With Incentives & Vaping E-cigarettes

Sponsor
Brown University (Other)
Overall Status
Recruiting
CT.gov ID
NCT06111053
Collaborator
National Institute of General Medical Sciences (NIGMS) (NIH)
36
1
4
15
2.4

Study Details

Study Description

Brief Summary

The purpose of this study is to provide preliminary information on the effect of electronic nicotine delivery systems (ENDS) provisions and contingent incentives (CI) on smoking in individuals with overweight/obesity who smoke cigarettes (SWO). All participants will be provided information on the comparative risk of ENDS relative to cigarette smoking, and a randomized group of participants will be provided ENDS provisions for 6 weeks. All participants will complete breath samples for 28 days to measure their exhaled carbon monoxide and will either receive fixed incentives for sample completion or receive varying incentives contingent on their carbon monoxide levels. Researchers will compare groups to understand the effect of each condition on smoking-related behavior.

Condition or Disease Intervention/Treatment Phase
  • Other: ENDS
  • Other: CI
  • Other: No ENDS
  • Other: NI
N/A

Detailed Description

Individuals with overweight/obesity who smoke cigarettes (SWO) have greatly increased risks of metabolic, cardiac, and pulmonary diseases due to the synergistic effects of tobacco and obesity. Switching to electronic nicotine delivery systems (ENDS) may decrease the risk of negative health outcomes and be a promising approach for SWO. The purpose of this study is to provide preliminary information on the effect of electronic nicotine delivery systems (ENDS) provisions and contingent incentives (CI) on individuals with overweight/obesity who smoke cigarettes (SWO). The primary aim of this study is to examine the effect of ENDS provision on smoking and the effect of the provision of CI provision on smoking. The secondary aims are to assess the effects of ENDS and CI provision on exhaled carbon monoxide (CO), cigarette dependence, intention to quit smoking, and quitting self-efficacy, and to determine whether any changes in weight occurred secondary to the use of ENDS. Evidence of the efficacy of switching to ENDS and the use of CI could be utilized in healthcare settings to reduce the risk of morbidity and mortality among smokers with obesity.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
36 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Intervention Model Description:
A 2x2 factorial design comparing contingent incentives (CI) for smoking abstinence to noncontingent incentives (NI) the provision of ENDS (ENDS) to no provision of ENDS (No ENDS) SWO (N=36) will be randomized to receive 4 weeks of monetary incentives contingent on their smoking abstinence (CI) or after completing breath samples only (NI). They will also be randomized to receive either a 6-week provision of ENDS with information communicating the comparative risk of ENDS use relative to smoking or information communicating the comparative risk of ENDS relative to smoking without ENDS provision. Conditions are as follows: C1: ENDS + CI C2: NoENDS + CI C3: ENDS + NI C4: NoENDS + NIA 2x2 factorial design comparing contingent incentives (CI) for smoking abstinence to noncontingent incentives (NI) the provision of ENDS (ENDS) to no provision of ENDS (No ENDS)SWO (N=36) will be randomized to receive 4 weeks of monetary incentives contingent on their smoking abstinence (CI) or after completing breath samples only (NI). They will also be randomized to receive either a 6-week provision of ENDS with information communicating the comparative risk of ENDS use relative to smoking or information communicating the comparative risk of ENDS relative to smoking without ENDS provision. Conditions are as follows:C1: ENDS + CI C2: NoENDS + CI C3: ENDS + NI C4: NoENDS + NI
Masking:
Single (Outcomes Assessor)
Masking Description:
Outcome assessor will not know the outcome of randomized assignment.
Primary Purpose:
Treatment
Official Title:
Harm Reduction in Smokers With Obesity: Impact of Contingent Incentives and E-Cigarettes
Actual Study Start Date :
Oct 2, 2023
Anticipated Primary Completion Date :
Jul 31, 2024
Anticipated Study Completion Date :
Dec 31, 2024

Arms and Interventions

Arm Intervention/Treatment
Experimental: ENDS and CI

Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking as well as 6 weeks' worth of provisions of ENDS and will receive 4 weeks of monetary incentives for complete abstinence from smoking (after a controlled ramp down of smoking).

Other: ENDS
Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
Other Names:
  • Electronic Nicotine Delivery Systems
  • Other: CI
    Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
    Other Names:
  • Contingent Incentives
  • Experimental: No ENDS and CI

    Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking and will receive 4 weeks of monetary incentives for complete abstinence from smoking (after a controlled ramp down of smoking).

    Other: CI
    Participants in active comparator groups will receive incentives that vary based on participant abstinence from smoking, measured by a carbon monoxide breath sample.
    Other Names:
  • Contingent Incentives
  • Other: No ENDS
    Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.

    Experimental: ENDS and NI

    Participants in this arm will receive information about the comparative risk of electronic nicotine delivery systems (ENDS) relative to smoking as well as 6 weeks' worth of provisions of ENDS and will receive monetary incentives for providing breath samples only (non-contingent on smoking status).

    Other: ENDS
    Participants in active comparator groups that include ENDS will receive 6-weeks worth of ENDS supplies.
    Other Names:
  • Electronic Nicotine Delivery Systems
  • Other: NI
    Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
    Other Names:
  • Non-Contingent Incentives
  • Experimental: No ENDS and NI

    Participants in this arm will receive information about the comparative risk of electronic nicotine devices (ENDs) relative to smoking and will receive monetary incentives for providing breath samples only (non-contingent on smoking status).

    Other: No ENDS
    Participants in active comparator groups labeled No ENDS will only receive information about the comparative risk of ENDS relative to combustible cigarettes.

    Other: NI
    Participants in active comparator groups labeled NI will receive compensation for each breath sample provided throughout the study, with no variation.
    Other Names:
  • Non-Contingent Incentives
  • Outcome Measures

    Primary Outcome Measures

    1. Use of Cigarettes and ENDS [Assessed 4, 6, and 12 weeks follow-up]

      Daily use of cigarettes and ENDS will be determined using the Timeline Follow-Back (TLFB) in follow-up assessments post-treatment.

    2. Within-Treatment Smoking Abstinence [Daily for 4 weeks]

      Number of days during the incentive period with CO verified abstinence from smoking

    Secondary Outcome Measures

    1. Motivation to change [Assessed 4, 6, and 12 weeks follow-up]

      Self-reported motivation, confidence, and importance of changing smoking and other tobacco & nicotine use behavior will be measured using motivation to change rulers

    2. Carbon monoxide (CO) [Assessed 4, 6, and 12 weeks follow-up]

      Exhaled breath sample used to measure carbon monoxide

    3. Cigarette and E-Cigarette Dependence [Assessed 4, 6, and 12 weeks follow-up]

      Self-reported level of dependence on cigarettes and e-cigarettes will be assessed using the Population Assessment of Tobacco and Health (PATH) Study dependence questionnaire. Items on this scale are scored from 1, "Not true of me at all", to 5, "Extremely true of me". Higher scores represent higher levels of cigarette and e-cigarette dependence. Minutes to first cigarettes daily will also be used to assess cigarette dependence with lower scores indicating greater cigarette dependence.

    4. Comparing E-Cigarettes and Cigarettes Questionnaire [Assessed 4, 6, and 12 weeks follow-up]

      Attitudes towards e-cigarettes relative to cigarettes (i.e., general benefits, general effects, and health benefits), will be assessed using the Comparing E-Cigarette and Cigarettes (CEAC) Questionnaire. Items on this questionnaire are scored from 1, "Strongly Disagree", to 5, "Strongly Agree" with higher score indicating greater agreement with benefits of e-cigarettes relative to cigarettes.

    5. Weight [Assessed 4, 6, and 12 weeks follow-up]

      Measured body weight in pounds

    Eligibility Criteria

    Criteria

    Ages Eligible for Study:
    21 Years to 99 Years
    Sexes Eligible for Study:
    All
    Accepts Healthy Volunteers:
    Yes
    Inclusion Criteria:
    • BMI ≥ 25 kg/m2

    • smoked ≥ 5 cigarettes/day during the past year

    • 21 or older

    • exhaled CO of > 6 ppm at Baseline

    • willing to use ENDs for 6 weeks

    • daily access to a Bluetooth-enabled smartphone/tablet

    Exclusion Criteria:
    • planning to set a smoking quit date in the next 30 days

    • receiving smoking cessation treatment of any kind in the past 30 days

    • currently using ENDS > 4 day per month

    • hospitalized for mental illness in past 30 days

    • heart-related event (e.g., heart attack, severe angina) in past 30 days

    • resides with another person enrolled in the study

    • pregnant, nursing, or planning to become pregnant in the next 6 months.

    Contacts and Locations

    Locations

    Site City State Country Postal Code
    1 Brown University School of Public Health Providence Rhode Island United States 02912

    Sponsors and Collaborators

    • Brown University
    • National Institute of General Medical Sciences (NIGMS)

    Investigators

    • Principal Investigator: Cara M Murphy, Ph.D., Brown University

    Study Documents (Full-Text)

    None provided.

    More Information

    Publications

    None provided.
    Responsible Party:
    Brown University
    ClinicalTrials.gov Identifier:
    NCT06111053
    Other Study ID Numbers:
    • 2022003359
    First Posted:
    Nov 1, 2023
    Last Update Posted:
    Nov 8, 2023
    Last Verified:
    Nov 1, 2023
    Individual Participant Data (IPD) Sharing Statement:
    Yes
    Plan to Share IPD:
    Yes
    Studies a U.S. FDA-regulated Drug Product:
    No
    Studies a U.S. FDA-regulated Device Product:
    No
    Keywords provided by Brown University
    Additional relevant MeSH terms:

    Study Results

    No Results Posted as of Nov 8, 2023